0709 203000 - Nairobi 0709 983000 - Kilifi
0709 203000 - NRB 0709 983000 - Kilifi
0709 203000 - NRB | 0709 983000 - Kilifi

Warimwe GM


62 results

Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations.Nyagwange J, Kutima B, Mwai K, Karanja HK, Gitonga JN, Mugo D, Uyoga S, Tuju J, Ochola-Oyier LI, Ndungu F, Bejon P, Agweyu A, Adetifa IMO, Scott JAG, Warimwe GM
J Clin Virol, (2022). 146:105061

Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya.Etyang AO, Lucinde R, Karanja H, Kalu C, Mugo D, Nyagwange J, Gitonga J, Tuju J, Wanjiku P, Karani A, Mutua S, Maroko H, Nzomo E, Maitha E, Kamuri E, Kaugiria T, Weru J, Ochola LB, Kilimo N, Charo S, Emukule N, Moracha W, Mukabi D, Okuku R, Ogutu M, Angujo B, Otiende M, Bottomley C, Otieno E, Ndwiga L, Nyaguara A, Voller S, Agoti CN, Nokes DJ, Ochola-Oyier LI, Aman R, Amoth P, Mwangangi M, Kasera K, Ng'ang'a W, Adetifa IMO, Wangeci Kagucia E, Gallagher K, Uyoga S, Tsofa B, Barasa E, Bejon P, Scott JAG, Agweyu A, Warimwe GM
Clin Infect Dis, (2022). 74:288-293

The global burden of Chikungunya fever among children: A systematic literature review and meta-analysis.Nyamwaya DK, Thumbi SM, Bejon P, Warimwe GM, Mokaya J
PLOS Global Public Health, (2022). 2:e0000914

Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data.Ojal J, Brand SPC, Were V, Okiro EA, Kombe IK, Mburu C, Aziza R, Ogero M, Agweyu A, Warimwe GM, Uyoga S, Adetifa IMO, Scott JAG, Otieno E, Ochola-Oyier LI, Agoti CN, Kasera K, Amoth P, Mwangangi M, Aman R, Ng'ang'a W, Tsofa B, Bejon P, Barasa E, Keeling MJ, Nokes DJ
Wellcome Open Res, (2021). 6:127

Quantifying previous SARS-CoV-2 infection through mixture modelling of antibody levels.Bottomley C, Otiende M, Uyoga S, Gallagher K, Kagucia EW, Etyang AO, Mugo D, Gitonga J, Karanja H, Nyagwange J, Adetifa IMO, Agweyu A, Nokes DJ, Warimwe GM, Scott JAG
Nat Commun, (2021). 12:6196

Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya.Kagucia EW, Gitonga JN, Kalu C, Ochomo E, Ochieng B, Kuya N, Karani A, Nyagwange J, Karia B, Mugo D, Karanja HK, Tuju J, Mutiso A, Maroko H, Okubi L, Maitha E, Ajuck H, Mukabi D, Moracha W, Bulimu D, Andanje N, Aman R, Mwangangi M, Amoth P, Kasera K, Ng'ang'a W, Nyaguara A, Voller S, Otiende M, Bottomley C, Agoti CN, Ochola-Oyier LI, Adetifa IMO, Etyang AO, Gallagher KE, Uyoga S, Barasa E, Bejon P, Tsofa B, Agweyu A, Warimwe GM, Scott JAG, Magarini Sub-County TDA SARS-CoV-2 Serosurveillance Team, The Busia County TDA SARS-CoV-Serosurveillance Team
Open Forum Infect Dis, (2021). 8:ofab314

COVID-19 transmission dynamics underlying epidemic waves in Kenya.Brand SPC, Ojal J, Aziza R, Were V, Okiro EA, Kombe IK, Mburu C, Ogero M, Agweyu A, Warimwe GM, Nyagwange J, Karanja H, Gitonga JN, Mugo D, Uyoga S, Adetifa IMO, Scott JAG, Otieno E, Murunga N, Otiende M, Ochola-Oyier LI, Agoti CN, Githinji G, Kasera K, Amoth P, Mwangangi M, Aman R, Ng'ang'a W, Tsofa B, Bejon P, Keeling MJ, Nokes DJ, Barasa E
Science, (2021). 374:989-994

Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021.Uyoga S, Adetifa IMO, Otiende M, Yegon C, Agweyu A, Warimwe GM, Scott JAG
JAMA, (2021). 326:1436-1438

What Constitutes Protective Immunity Following Yellow Fever Vaccination?.Mokaya J, Kimathi D, Lambe T, Warimwe GM
Vaccines (Basel), (2021). 9:671

Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.Adetifa IMO, Uyoga S, Gitonga JN, Mugo D, Otiende M, Nyagwange J, Karanja HK, Tuju J, Wanjiku P, Aman R, Mwangangi M, Amoth P, Kasera K, Ng'ang'a W, Rombo C, Yegon C, Kithi K, Odhiambo E, Rotich T, Orgut I, Kihara S, Bottomley C, Kagucia EW, Gallagher KE, Etyang A, Voller S, Lambe T, Wright D, Barasa E, Tsofa B, Bejon P, Ochola-Oyier LI, Agweyu A, Scott JAG, Warimwe GM
Nat Commun, (2021). 12:3966

Using cross-species vaccination approaches to counter emerging infectious diseases.Warimwe GM, Francis MJ, Bowden TA, Thumbi SM, Charleston B
Nat Rev Immunol, (2021). 21:815-822

Endemic chikungunya fever in Kenyan children: a prospective cohort study.Nyamwaya DK, Otiende M, Omuoyo DO, Githinji G, Karanja HK, Gitonga JN, de Laurent ZR, Otieno JR, Sang R, Kamau E, Cheruiyot S, Otieno E, Agoti CN, Bejon P, Thumbi SM, Warimwe GM
BMC Infect Dis, (2021). 21:186

Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.Juan-Giner A, Kimathi D, Grantz KH, Hamaluba M, Kazooba P, Njuguna P, Fall G, Dia M, Bob NS, Monath TP, Barrett AD, Hombach J, Mulogo EM, Ampeire I, Karanja HK, Nyehangane D, Mwanga-Amumpaire J, Cummings DAT, Bejon P, Warimwe GM, Grais RF
Lancet, (2021). 397:119-127

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors.Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, Aman R, Mwangangi M, Amoth P, Kasera K, Ng'ang'a W, Rombo C, Yegon C, Kithi K, Odhiambo E, Rotich T, Orgut I, Kihara S, Otiende M, Bottomley C, Mupe ZN, Kagucia EW, Gallagher KE, Etyang A, Voller S, Gitonga JN, Mugo D, Agoti CN, Otieno E, Ndwiga L, Lambe T, Wright D, Barasa E, Tsofa B, Bejon P, Ochola-Oyier LI, Agweyu A, Scott JAG, Warimwe GM
Science, (2021). 371:79-82

Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations..Nyagwange J, Kutima B, Mwai K, Karanja HK, Gitonga JN, Mugo D, Uyoga S, Tuju J, Ochola-Oyier LI, Ndungu F, Bejon P, Agweyu A, Adetifa IMO, Scott JAG, Warimwe GM
1st International Conference on Public Health in Africa (CPHIA), (2021). :

Prevalence of anti-SARS-CoV-2 IgG antibodies among Kenyan blood donors between June and August 2021..Uyoga S, Otiende M, Adetifa IMO, Karanja HK, Gitonga J, Mugo D, Makale J, Tawa B, Singilai A, Nyagwange J, Tuju J, Aman R, Mwangangi M, Amoth P, Kasera K, Ng�ang�a W, Kilonzo N, Chege E, Yegon C, Rotich T, Orgut I, Kagucia EW, Gallagher KE, Etyang A, Voller S, Bottomley C, Lambe T, Wright D, Tsofa B, Mwangangi J, Barasa E, Bejon P, Ochola-Oyier LI, Warimwe GM, Scott JAG, Agweyu A
1st International Conference on Public Health in Africa (CPHIA), (2021). :

High anti-SARS-CoV-2 IgG antibody seroprevalence among long-distance trucking crews in Kenya within one year of the COVID-19 pandemic..Kagucia EW, Gitonga JN, Kalu C, Kuya N, Ochieng B, Karia B, Ochomo E, Karani A, Nyagwange J, Mugo D, Karanja HK, Tuju J, Mutiso A, Maroko H, Okubi L, Maitha E, Mukabi D, The TDA SARS-CoV-2 Serosurveillance Team, Aman R, Mwangangi M, Amoth P, Kasera K, Ng�ang�a W, Nyaguara A, Voller S, Otiende M, Bottomley C, Agoti CN, Ochola-Oyier LI, Adetifa IMO, Etyang AO, Gallagher KE, Uyoga S, Barasa E, Bejon P, Tsofa B, Agweyu A, Warimwe GM, Scott JAG
1st International Conference on Public Health in Africa (CPHIA), (2021). :

Serosurveillance for SARS-CoV-2 Antibodies in a cohort of Health Care Workers in Kenya..Etyang AO, Lucinde R, Gitonga JN, Kalu C, Karani A, Nyagwange J, Mugo D, Karanja HK, Tuju J, Mutiso A, Maroko H, Okubi L, Maitha E, Mukabi D, The HCW SARS-CoV-2 Serosurveillance Team, Aman R, Mwangangi M, Amoth P, Kasera K, Ng�ang�a W, Nyaguara A, Voller S, Otiende M, Bottomley C, Agoti CN, Ochola-Oyier LI, Adetifa IMO, Gallagher KE, Uyoga S, Barasa E, Bejon P, Tsofa B, Agweyu A, Warimwe GM, Scott JAG
1st International Conference on Public Health in Africa (CPHIA), (2021). :

Genomic surveillance of SARS-CoV-2 in Kenya: March 2020-October 2021..Githinji G, Lambisia WA, Mohamed KS, Morobe MJ, de Laurent ZR, Mburu WM, Ongera ME, Omuoyo OD, Ndwiga L, Otieno E, Murunga N, Musyoki J, KWTRP COVID Testing Team, Kilifi Rapid Response Team, Kiiru J, Kasera K, Amoth P, Mwangangi M, Aman R, Kinyanjui S, Warimwe GM, Agweyu A, Barasa E, Tsofa B, Mwangangi J, Matoke D, Nokes DJ, Bejon P, Ochola-Oyier LI, Agoti CN
1st International Conference on Public Health in Africa (CPHIA-2021), (2021). :

Naturally Acquired Rift Valley Fever Virus Neutralizing Antibodies Predominantly Target the Gn Glycoprotein.Wright D, Allen ER, Clark MHA, Gitonga JN, Karanja HK, Hulswit RJG, Taylor I, Biswas S, Marshall J, Mwololo D, Muriuki J, Bett B, Bowden TA, Warimwe GM
iScience, (2020). 23:101669